Article courtesy of Science Alert
Australian researchers are fast-tracking large-scale human testing to see if a vaccine used for decades to prevent tuberculosis can protect health workers from COVID-19, they announced Friday.
The trial of the BCG vaccine will be conducted with 4,000 health workers in hospitals around Australia to determine if it can reduce COVID-19 symptoms, the researchers at the Murdoch Children’s Research Institute in Melbourne said.
“Although originally developed against tuberculosis, and still given to over 130 million babies annually for that purpose, BCG also boosts humans’ ‘frontline’ immunity, training it to respond to germs with greater intensity,” they said in a statement.
“We hope to see a reduction in the prevalence and severity of COVID-19 symptoms in healthcare workers receiving the BCG vaccination,” said lead researcher Nigel Curtis.
He said the 4,000 subjects would be enrolled in the trial within weeks under a fast-tracked process with the approval of state and federal health authorities. “The clock is definitely ticking,” he said.
Similar trials are being conducted in several other countries including the Netherlands, Germany and the United Kingdom.
“This trial will allow the vaccine’s effectiveness against COVID-19 symptoms to be properly tested, and may help save the lives of our heroic frontline healthcare workers,” said Kathryn North, director of the Murdoch Institute.
She said the hope was that improving people’s “innate” immunity against COVID-19 symptoms would buy time to develop a specific vaccine against the disease.
“These trials will allow the rapid advancement of the most promising candidates to clinical practice, giving us the most number of shots on goal against COVID-19 as possible,” she said.
THE INFORMATION ABOVE IS FOR INFORMATION PURPOSES ONLY. IT IS THE RESPONSIBILITY OF EACH INDIVIDUAL TO MANAGE THEIR OWN HEALTH AND WELLBEING AND THEY ALONE ARE SOLELY RESPONSIBLE FOR ALL DECISIONS MADE IN THIS RESPECT. THE INFORMATION ABOVE COULD BE CONSIDERED BY AN INDIVIDUALS MEDICAL PROFESSIONAL WHEN INVESTIGATING PREVENTION MEASURES AND TREATMENT FOR CORONAVIRUS. THE ABOVE SHOULD NOT BE CONSIDERED TO BE ADVICE TO FOLLOW WITHOUT FIRST CONSULTING YOUR MEDICAL PROFESSIONAL WHO IS ABLE TO ADVISE ON THE SUITABILITY, RISK AND BENEFITS WITH RESPECT TO EACH INDIVIDUAL AFTER TAKING ACCOUNT OF EACH PERSONS PARTICULAR CIRCUMSTANCES, MEDICAL HISTORY, PRE-EXISTING CONDITIONS, ALLERGIES AND OTHER RELEVANT MEDICAL FACTORS.
DO NOT USE THE ABOVE INFORMATION TO DIAGNOSE, TREAT, CURE OR PREVENT ANY DISEASE, SICKNESS OR AILMENT, FOR THERAPEUTIC PURPOSES OR AS A SUBSTITUTE FOR THE ADVICE OF A HEALTH PROFESSIONAL. INDIVIDUALS USING THE ABOVE INFORMATION DO SO AT THEIR SOLE RISK AND THEY TOGETHER WITH THEIR FAMILY, AGENTS, EXECUTORS AND ASSIGNS FULLY RELEASE AND HOLD HARMLESS MRS GINA RINEHART, HANCOCK PROSPECTING PTY LTD, ITS DIRECTORS, OFFICERS, SUBSIDIARIES AND RELATED ENTITIES FROM ANY CLAIMS, DAMAGES, DISTRESS OR OTHERWISE THAT MAY BE SUFFERED, ARISE OR BE CAUSED IN ANY WAY WHATSOEVER FROM FOLLOWING, RELYING ON, OR IN ANY WAY WHATSOEVER READING OR USING THE INFORMATION ABOVE.
MRS GINA RINEHART, HANCOCK PROSPECTING PTY LTD, ITS DIRECTORS, OFFICERS, ITS SUBSIDIARIES AND RELATED ENTITIES TAKE NO RESPONSIBILITY FOR THE VERACITY OF THE INFORMATION SHOWN ABOVE AND TO THE FULLEST EXTENT POSSIBLE DISCLAIM ALL AND ANY LIABILITY FOR ANY DIRECT, INDIRECT, SPECIAL, EXEMPLARY OR OTHER DAMAGES OR NEGATIVE HEALTH EFFECTS THAT MAY ARISE FROM UTILISING ANY OF THE ABOVE INFORMATION SHOULD ANY MEDICAL PROFESSIONAL OR INDIVIDUAL CHOOSE TO FOLLOW ANY PART OF THE ABOVE INFORMATION. PLEASE DO NOT READ FURTHER UNLESS YOU AGREE THAT YOU WILL NOT AT ANY TIME SEEK TO HOLD MRS GINA RINEHART, HANCOCK PROSPECTING PTY LTD, ITS DIRECTORS, OR OFFICERS OR ANY OF ITS SUBSIDIARIES OR ITS RELATED ENTITIES RESPONSIBLE IN ANY WAY.